Drug reference

Fremanezumab

Monoclonal Antibody · Migraine Prophylaxis

Also known as Ajovy

Monoclonal AntibodyMigraine Prophylaxis

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Manufacturer advises avoid—limited information available.

FDA category + note

Mechanism

Fremanezumab is a humanised monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand. By binding to CGRP, it inhibits the function of CGRP at its receptor, preventing its binding and activation of the receptor. This action helps to prevent migraine attacks.

Indications

Prophylaxis of migraine in patients who have at least 4 migraine days per month (initiated by a specialist)

Dosing

Adult: Subcutaneously once per month

Pharmacokinetics

Duration

Monthly

Contraindications

Major cardiovascular disease (no information available)

Side effects

Serious

Hypersensitivity

Pregnancy & lactation

Pregnancy

Manufacturer advises avoid—limited information available.

Lactation

Manufacturer advises avoid during ﬁrst few days after birth—possible risk from transfer of antibodies to infant. After this time, use during breastfeeding only if clinically needed.